Bloomsbury Publishing Plc 4.2% potential upside indicated by Numis

Bloomsbury Publishing Plc with ticker (LON:BMY) now has a potential upside of 4.2% according to Numis.



Numis set a target price of 475 GBX for the company, which when compared to the Bloomsbury Publishing Plc share price of 456 GBX at opening today (30/03/2023) indicates a potential upside of 4.2%. Trading has ranged between 356 (52 week low) and 493 (52 week high) with an average of 182,024 shares exchanging hands daily. The market capitalisation at the time of writing is £366,830,926.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.